Rani Therapeutics Holdings (RANI) Non-Current Deffered Revenue (2025)
Rani Therapeutics Holdings (RANI) posted Non-Current Deffered Revenue of $1.7 million for Q4 2025.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Non-Current Deffered Revenue (2025) Analysis & Trends
Rani Therapeutics Holdings has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $1.7 million in Q4 2025.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $1.7 million in Q4 2025; TTM through Dec 2025 was $1.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $1.7 million for Q4 2025 at Rani Therapeutics Holdings.
- The five-year high for Non-Current Deffered Revenue was $1.7 million in Q4 2025, with the low at $1.7 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | - |